Development and preparation of the EIC Accelerator application: First-in-human trial of CAR13(NAP)-T cells in patients with relapsed glioblastoma.
| Reference number | |
| Coordinator | Elicera Therapeutics AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | June 2025 - October 2025 |
| Status | Completed |
| Venture | Global cooperation 2025 |
| Call | Planning grant for international proposal 2025 |
Important results from the project
Ja.
Expected long term effects
An innovative CAR T-cell therapy is expected to be offered to glioblastoma patients that are in desperate need of new treatment options.
Approach and implementation
GAEU Consulting hade ett team på tre personer med olika kompetenser som vid sidan av ett team på tre personer från Elicera arbetade fram en stark bidragsansökan till EIC Accelerator Fund.